Square Pharmaceuticals Limited, a publicly traded company, reported 16% up in profit in third quarter (January-March) of the current FY20 compared to same period of the previous year.
The company's net profit stood at Tk361.54 crore, against Tk311.79 crore in the same quarter of the previous year, as per an official disclosure posted by the company on Dhaka Stock Exchange (DSE) website on Tuesday.
According to un-audited financial statement, the consolidated earnings per share (EPS) of Square Pharma was Tk 4.28 for the period, against Tk3.69 for the same period last year.
The novel coronavirus outbreak helped augment its drug sales, resulting in the higher profitability, said an official of the pharma company.
In nine months (July-March of FY20), the company’s consolidated net profit stood at Tk 1,050 crore for the period of July, 2019 to March 31, 2020 which was Tk 942 crore in the same period of the previous year.
The company’s consolidated EPS was Tk 12.44 for July 01, 2019 to March 31, 2020 as against Tk 11.15 for July 1, 2018 to March 31, 2019.
The company disbursed 42% cash and 7% stock dividend for the year ended on June 30, 2019.
In 2018, the pharma company disbursed 36% cash and 7% stock dividend. In 2017, 35% cash and 7.50% stock dividend disbursed. In 2016, the pharma company’s disbursed 40% cash and 10% stock dividend.
Square Pharmaceuticals, one of the leading pharma companies, manufactures and markets various generic pharmaceuticals products, basic chemicals, and animal health products. The company holds 17.73% of pharmaceutical market share.
